Bristol-Myers Squibb Balance Sheet Health
Financial Health criteria checks 3/6
Bristol-Myers Squibb has a total shareholder equity of $17.4B and total debt of $49.7B, which brings its debt-to-equity ratio to 285.1%. Its total assets and total liabilities are $92.4B and $75.0B respectively. Bristol-Myers Squibb's EBIT is $11.1B making its interest coverage ratio 7. It has cash and short-term investments of $11.8B.
Key information
285.09%
Debt to equity ratio
US$49.74b
Debt
| Interest coverage ratio | 7x |
| Cash | US$11.78b |
| Equity | US$17.45b |
| Total liabilities | US$74.98b |
| Total assets | US$92.43b |
Recent financial health updates
No updates
Recent updates
We Think Bristol-Myers Squibb's (NYSE:BMY) Robust Earnings Are Conservative
May 05
Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession
Apr 22Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold
Mar 25Bristol-Myers Squibb: Why I'm Still Bullish
Mar 18
Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value
Total Revenues: $12.3 billion, an 8% increase from the same period in 2023.Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Feb 21Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Feb 07Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain
Jan 31Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62
Dec 29Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Dec 20Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year
Dec 15Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)
Nov 275 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)
Nov 25Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren
Oct 28Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon
Oct 06Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Sep 27Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows
Sep 06Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues
Aug 15Bristol-Myers Squibb: A Potential Comeback In Healthcare
Aug 06Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point
Jul 27Bristol Myers Squibb: The More It Drops, The More I Buy
Jul 16Financial Position Analysis
Short Term Liabilities: BMY's short term assets ($30.8B) exceed its short term liabilities ($24.1B).
Long Term Liabilities: BMY's short term assets ($30.8B) do not cover its long term liabilities ($50.9B).
Debt to Equity History and Analysis
Debt Level: BMY's net debt to equity ratio (217.6%) is considered high.
Reducing Debt: BMY's debt to equity ratio has increased from 93.5% to 285.1% over the past 5 years.
Debt Coverage: BMY's debt is well covered by operating cash flow (28.8%).
Interest Coverage: BMY's interest payments on its debt are well covered by EBIT (7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/26 03:26 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bristol-Myers Squibb Company is covered by 47 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Charles Butler | Barclays |